Mounjaro Cost in New York (2026): Insurance, Medicaid, and Savings Options

What Mounjaro Actually Costs at a New York Pharmacy

The retail price for brand-name Mounjaro at most New York pharmacies sits at $1,023 per month in 2026, matching the Eli Lilly wholesale acquisition cost. That figure applies regardless of dose, whether you fill a 2.5 mg starter pen or a 15 mg maintenance pen. Without insurance or a savings program, this is the price you pay.

Tirzepatide earned FDA approval in May 2022 as a once-weekly GIP/GLP-1 receptor agonist for type 2 diabetes under the brand name Mounjaro. Eli Lilly later received approval for the same molecule under the brand name Zepbound specifically for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. The two share identical active ingredients but carry different NDC codes, formulary placements, and coverage pathways.

New York pharmacy pricing shows minimal variation across the five boroughs and upstate regions. A GoodRx or RxSaver coupon may trim the cash price by 5% to 12% at select chains, but the discount rarely drops the monthly cost below $900. The real savings come from insurance benefits, manufacturer programs, or compounded alternatives, each of which we break down below.

New York Medicaid Coverage for Mounjaro

New York Medicaid covers Mounjaro with prior authorization for adults diagnosed with type 2 diabetes. The PA requirement typically means the prescriber must document a hemoglobin A1c at or above 7% and show that the patient tried metformin (or has a documented contraindication) before approval.

Coverage does not extend to weight loss alone under the Mounjaro label for most managed Medicaid plans in New York. The state follows CMS guidance that anti-obesity medications remain a statutory exclusion under traditional Medicaid unless a state explicitly opts in. New York has not yet enacted a Medicaid carve-in for obesity pharmacotherapy as of May 2026, though several legislative proposals are under review.

For type 2 diabetes indications, approval rates are high once documentation is submitted. A 2023 analysis of commercial and Medicaid PA outcomes for GLP-1 receptor agonists found that properly documented first-time requests achieved approval rates above 80%. Patients enrolled in Medicaid managed care plans (such as Healthfirst, Fidelis Care, or MetroPlus in New York City) should confirm their specific plan formulary, as tier placement and step-therapy requirements can vary by MCO.

Which New York Insurance Plans Cover Mounjaro

Most major commercial insurers operating in New York, including UnitedHealthcare, Aetna, Cigna, and Empire BlueCross BlueShield, include Mounjaro on their formularies for type 2 diabetes. Tier placement varies. Some plans list it as a preferred brand (Tier 2) with copays between $35 and $75. Others place it on a specialty tier (Tier 4 or 5) with coinsurance of 25% to 33%, translating to $250 to $340 per month before any manufacturer offset.

Coverage for weight management specifically requires the Zepbound label. A growing number of New York employer-sponsored plans added obesity pharmacotherapy benefits in 2025 and 2026 following the American Association of Clinical Endocrinology updated guidelines recommending GLP-1 or dual GIP/GLP-1 agonists as first-line pharmacotherapy for obesity. The SURMOUNT-1 trial data, which showed tirzepatide 15 mg produced 22.5% mean body weight reduction versus 2.4% for placebo at 72 weeks (N=2,539), strengthened the clinical case for payer adoption.

New York State employees covered under the Empire Plan gained Mounjaro access for type 2 diabetes in 2023. Check your plan's Summary of Benefits and Coverage document or call the number on the back of your insurance card to confirm your specific tier and PA requirements. Step therapy often mandates a trial of metformin and at least one sulfonylurea or SGLT2 inhibitor before the plan approves tirzepatide.

How the Eli Lilly Mounjaro Savings Card Works in New York

Eli Lilly's Mounjaro Savings Card allows commercially insured patients to pay as little as $25 per fill for up to 24 months. The card functions as a secondary payer: your pharmacy runs your primary insurance first, and the savings card covers the remaining copay or coinsurance up to a set maximum (currently $573 per 28-day fill in most program iterations).

Eligibility requirements are straightforward. You must carry commercial insurance (not Medicare, Medicaid, Tricare, or any other government-funded plan), have a valid Mounjaro prescription, and activate the card through the Lilly website or through your prescriber's office. New York residents face no state-specific restrictions on using manufacturer copay cards for commercially insured prescriptions.

Patients without any insurance do not qualify for the savings card. Lilly runs a separate patient assistance program (Lilly Cares) for uninsured individuals earning below 400% of the federal poverty level, providing Mounjaro at no cost. This is a critical distinction. The savings card and the patient assistance program are two separate pathways with different eligibility criteria.

Compounded Tirzepatide in New York: Legality and Cost

Compounded tirzepatide from 503A pharmacies is legal in New York. Licensed compounding pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act may prepare tirzepatide for individual patients with valid prescriptions. The New York State Board of Pharmacy applies strict oversight, requiring that 503A pharmacies comply with USP 797 sterile compounding standards and maintain proper documentation.

The average price for compounded tirzepatide in New York is approximately $249 per month. That figure represents a 75% reduction from the brand-name cost. Pricing varies by pharmacy, dose, and whether the formulation is supplied as a multi-dose vial or prefilled syringe.

There are trade-offs to consider. Compounded drugs are not FDA-approved and do not undergo the same bioequivalence testing required of generic medications. Potency, sterility, and stability depend entirely on the compounding pharmacy's quality controls. The FDA issued a safety alert in 2023 regarding adverse events linked to compounded semaglutide products, and similar concerns apply to any compounded peptide.

Before choosing a compounded product, verify that the pharmacy holds a valid New York State license, operates under a current USP 797 inspection, and can provide a Certificate of Analysis for the tirzepatide it dispenses. Your prescriber should be comfortable with compounded formulations and willing to monitor your response with the same lab schedule they would use for brand-name Mounjaro, including periodic A1c and fasting glucose checks.

Clinical Efficacy: What You Get for the Cost

Mounjaro's price reflects a dual-mechanism drug with strong trial data. The SURPASS-2 trial (N=1,879) compared tirzepatide at 5 mg, 10 mg, and 15 mg against semaglutide 1 mg in adults with type 2 diabetes. At 40 weeks, tirzepatide 15 mg reduced A1c by 2.46% versus 1.86% for semaglutide 1 mg, a statistically significant difference (P<0.001 for superiority). The 15 mg dose also produced 12.4 kg of mean weight loss compared to 6.2 kg with semaglutide.

These results carried through longer studies. The SURPASS-4 trial followed patients for up to 104 weeks and showed sustained A1c reductions and cardiovascular risk factor improvement with tirzepatide versus insulin glargine. For weight management specifically, the SURMOUNT-1 trial demonstrated that 36% of participants on tirzepatide 15 mg lost at least 25% of their body weight at 72 weeks.

Dr. Ania Jastreboff, the lead investigator of SURMOUNT-1, stated that "tirzepatide achieved unprecedented levels of weight reduction in the clinical trial setting." The Endocrine Society's 2023 clinical practice guideline on pharmacological management of obesity lists tirzepatide among the highest-efficacy agents available.

The cost-effectiveness question depends on your clinical scenario. A 2024 Institute for Clinical and Economic Review (ICER) analysis estimated that tirzepatide for type 2 diabetes met commonly cited willingness-to-pay thresholds at net pricing after rebates, though the list price without discounts exceeded most benchmarks for obesity treatment alone.

Telehealth Options for Mounjaro in New York

New York permits telehealth prescribing of Mounjaro. Prescribers licensed in New York State may evaluate patients via synchronous audio-video visits and issue prescriptions for controlled and non-controlled medications, including GLP-1 and GIP/GLP-1 agonists. The Ryan Haight Act exemptions and DEA telehealth flexibilities do not directly apply to Mounjaro since tirzepatide is not a scheduled substance, simplifying the telehealth pathway.

HealthRX and other licensed telehealth platforms operating in New York can prescribe Mounjaro or Zepbound after a clinical evaluation that includes review of medical history, current medications, relevant labs (A1c, metabolic panel, and potentially thyroid function), and BMI documentation. The prescription is sent electronically to the patient's pharmacy of choice, including compounding pharmacies if applicable.

Telehealth visits often cost less than in-office endocrinology consultations. Initial visits through most platforms range from $99 to $199, with follow-ups at $49 to $99. This is relevant to the total cost of care: the drug price is only one component. Lab work, provider visits, and ongoing monitoring add $300 to $800 annually depending on your insurance and visit frequency, consistent with ADA Standards of Care recommendations for quarterly to semi-annual diabetes monitoring.

How to Reduce Your Mounjaro Cost in New York

The lowest-cost path depends on your insurance status. Here is a decision framework by coverage type:

Commercially insured (type 2 diabetes): File for prior authorization through your prescriber, then activate the Eli Lilly Savings Card. Out-of-pocket cost: $25 to $75 per month in most scenarios.

Commercially insured (weight management): Request Zepbound specifically. If your plan covers anti-obesity medications, follow the same PA and savings card approach. If not, ask your prescriber about a type 2 diabetes indication if clinically appropriate based on ADA diagnostic criteria.

New York Medicaid (type 2 diabetes): Your prescriber submits PA documentation. No copay or minimal copay once approved.

Uninsured: Apply for Lilly Cares patient assistance (income below 400% FPL). If ineligible, compounded tirzepatide at approximately $249 per month through a licensed New York 503A pharmacy is the most affordable option.

Medicare Part D: Mounjaro coverage varies by plan. The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D spending that took effect in 2025 limits total yearly exposure, but monthly costs early in the coverage year may still exceed $300 before reaching the cap.

Regardless of your payment pathway, a baseline A1c, lipid panel, and renal function panel should precede your first injection, and your prescriber should reassess A1c at 12 weeks to confirm glycemic response and justify continued coverage to your insurer.